Results 51 to 60 of about 19,727 (209)

Improving access to direct acting antivirals via a multimodal integrated care program in an addiction medicine clinic

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Injection drug use is a driver of hepatitis C virus (HCV) transmission, thus integrating HCV care into addiction care is likely necessary for HCV elimination. Here we describe how we integrated HCV care into our addiction medicine (AM) clinic and evaluate its effect on HCV treatment.
Arya Zandvakili, Joseph Rattenni, James Burton, Lakshmi Guduguntla, Marcus Osman, Sayeh Sabbagh, Stephan Arndt, Ben Miskle, Quanhathai Kaewpoowat, Michael Ohl, Andrea Weber, Alison Lynch   +11 more
wiley   +1 more source

NOVEL DIRECT ACTING ANTIVIRAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C AND CHRONIC KIDNEY DISEASE STAGE 3 TO STAGE 5D

Pakistan Armed Forces Medical Journal, 2020
Objective: To assess the safety and efficacy of Sofosbuvir based Antiviral regimens for chronic hepatitis C virus infected patients with chronic kidney disease stage 3 to stage 5D on haemodialysis. Study Design: Quasi experimental study.
Nauman Kashif, Zahid Farooq Baig, Shahzad Ashraf   +2 more
doaj  

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Hydrogen Bonding (Base Pairing) in Antiviral Activity

Viruses, 2023
Base pairing based on hydrogen bonding has, since its inception, been crucial in the antiviral activity of arabinosyladenine, 2′-deoxyuridines (i.e., IDU, TFT, BVDU), acyclic nucleoside analogues (i.e., acyclovir) and nucleoside reverse transcriptase ...
Erik De Clercq
doaj   +1 more source

A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection [PDF]

, 2016
Background: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been ...
Alavian, Seyed Moayed, Kebriaeezadeh, Abbas, Keshavarz, Khosro, Lotfi, Farhad, Nikfar, Shekoufeh, Rezaei Hemami, Mohsen, Sanati, Ehsan   +6 more
core   +1 more source

Post‐to Pretreatment Ratio of Serum CXCL10 Level Predicts Short‐Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct‐Acting Antiviral Therapy

Hepatology Research, EarlyView.
The post‐to pretreatment serum CXCL10 ratio was independently associated with short‐term liver function outcome following HCV eradication in cirrhotic patients. ABSTRACT Aim The prognostic value of serum C‐X‐C motif chemokine ligand 10 (CXCL10) levels for liver function was investigated in hepatitis C virus (HCV)–infected patients with compensated or ...
Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, Hayato Hikita, Masaru Enomoto, Atsunori Tsuchiya, Daiki Miki, Hiroshi Yatsuhashi, Hidekatsu Kuroda, Taro Yamashita, Hitoshi Yoshiji, Nobuharu Tamaki, Seiichi Mawatari, Hisamitsu Miyaaki, Yasuhiro Asahina, Yoichi Hiasa, Yoshihito Uchida, Yasunari Nakamoto, Taro Takami, Takahiro Kodama, Tetsuo Takehara   +20 more
wiley   +1 more source

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis

Diseases
Background: There is still debate whether ribavirin should be added to direct-acting antivirals (DAAs) for the management of treatment-experienced individuals with non-genotype-1 hepatitis C.
Shahd Hamran, Amani A. Al-Rajhi, Kawthar Jasim, Majed A. Al-Theyab, Mohamed Elahtam, Mooza K. Al-Hail, Wadha Al-Fahaidi, Yaman A. Khamis, Yara Dweidri, Abdel-Naser Elzouki, Tawanda Chivese   +10 more
doaj   +1 more source

PBPK Evaluation of Sofosbuvir Dose in Pediatrics Using Simcyp^®

Scientia Pharmaceutica, 2023
The aim of the study is to evaluate the effectiveness of the pediatric sofosbuvir weight-based dosing strategy in providing an equitable drug exposure compared to the marketed dose. The physiologically based pharmacokinetic (PBPK) modeling and simulation
Rania Elkeeb, Anomeh Avartoomian, Amira S. Gouda, Ahmed M. Abdel-Megied, Ola Abdallah, Eman Atef   +5 more
doaj   +1 more source

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela, Corach, Daniel, Flichman, Diego Martin, Hulaniuk, María L., Trinks, Julieta   +4 more
core   +1 more source

The costs and benefits of a prison needle and syringe program in Australia, 2025–30: a modelling study

Medical Journal of Australia, Volume 222, Issue 8, Page 396-402, May 2025.
Abstract Objectives To estimate and compare the costs and benefits of introducing a prison needle and syringe program in all Australian prisons. Study design Stochastic compartmental modelling study. Setting All Australian prisons, 1 January 2010 to 31 December 2030.
Farah Houdroge, Samantha Colledge‐Frisby, Nadine Kronfli, Rebecca J Winter, Joanne Carson, Mark Stoove, Nick Scott   +6 more
wiley   +1 more source